{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Diseases of the digestive system"],"disease":["Diseases Of The Digestive System"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2511337"],"location":["South Korea"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in colorectal cancer patients","description":"Interventions: Drug : Experimental group takes olanzapine 5mg po a day for 3days.\nControl group takes placebo 5mg po a day for 3days.\nPrimary outcome(s): Check the patient experience nausea or vomitting\nPrimary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT","dates":{"creation":"2018-01-15"},"accession":"2511337","cross_references":{"Clinical Research Information Service":["KCT0003288"]}}